IMCgp100-202
16 Oct 2017
Trial Summary
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Acronym:
IMCgp100-202
ACTRN/NCT /ethics:
NCT03070392
Scientific title:
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Sponsor / Cooperative group:
Immunocore
Summary:
A phase II randomized, open-label, multi-centre study of the safety and efficacy of IMCgp100 compared with Investigator choice in HLA-A*0201 positive patients with previously untreated advanced uveal melanoma.
Trial & patient characteristics
| Cancer Type | Melanoma/Skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18+ years |
| Sex | Both |
| Tumour Stream | Uveal Melanoma |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2017-10-16 |
| Anticipated End Date | tbc |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Professor Michael Brown |
| Recruitment Status | Recruiting |